To examine if patients with preclinical AD can administer IN insulin (Humulin R U‐100) using delivery device four times daily over a 4 week period and will assess its impact on cognition, CSF biomarkers, and cerebral perfusion. The gene discussed is INS; the disease is Alzheimer disease.